Kardigan aims to concentrate on developing specific medications for this condition.
View pictures in App save up to 80% data.
When Bristol Myers Squibb bought the heart disease-focused biotech MyoKardia for $13 billion in cash in the fall of 2020, it was seen as an endorsement of advances being made in cardiology, an area the drug industry was increasingly ignoring. But for MyoKardia’s CEO, Tassos Gianakakos, it represented a bit of a problem: He “fell in love” with cardiology, and he was also almost instantly out of a job.
On Friday, he revealed that he and the executive team at MyoKardia have successfully secured $300 million in funding for a new venture, Kardigan, which aims to develop targeted therapies for heart disease. The Series A financing has been backed by three leading venture capital firms: Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage. Kardigan, which operates out of South San Francisco and Princeton, New Jersey, currently employs approximately 60 staff members.
"I began contemplating this almost immediately after BMS acquired MyoKardia, as I felt like I was gently ushered out," Gianakakos remarked. "I truly mean that in a positive and endearing sense."
STAT+ Premium Feature
Already have an account? Log in
View pictures in App save up to 80% data.
This piece is available solely for STAT+ subscribers.
Access this article along with comprehensive analysis, exclusive newsletters, premium events, and timely news alerts.
Already have an account? Log in
每月
$39
The annual total amounts to $468.
The annual total amounts to $468.
Beginner
$30
for a duration of 3 months, followed by an annual fee of $399.
After that, it's $399 per year.
Yearly
$399
Get a 15% discount!
Get a 15% discount!
11 or more users
You have been trained on information available until October 2023.
Enjoy discounts starting from 25%!
Enjoy discounts starting from 25%!
2 to 10 Users
$300
Yearlyly per user
$300 Yearlyly per user
To continue reading this story, please subscribe to STAT+.
